Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies

详细信息    查看全文

• 作者：Joleen M. Hubbard ; George Kim ; Mitesh J. Borad…
• 关键词：Colorectal cancer ; Systemic therapy ; Antiangiogenesis
• 刊名：Investigational New Drugs
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：34
• 期：1
• 页码：96-103
• 全文大小：276 KB
• 参考文献：1.Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA Cancer J Clin 64(2):104–117. doi:10.​3322/​caac.​21220 PubMed CrossRef
  2.Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD, Cancer, Leukemia Group B S, ECOG (2014) CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). ASCO Meeting Abstracts 32 (18_suppl):LBA3
  3.Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson 3rd AB (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25(12):1539–1544PubMed CrossRef
  4.Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMed CrossRef
  5.Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343(13):905–914PubMed CrossRef
  6.Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, Steffens CC, Alonso-Orduna V, Schlichting C, Reyes-Rivera I, Bendahmane B, Andre T, Kubicka S, Investigators MLS (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncology 14(1):29–37. doi:10.​1016/​S1470-2045(12)70477-1 PubMed CrossRef
  7.Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol Off J Am Soc Clin Oncol 30(28):3499–3506. doi:10.​1200/​JCO.​2012.​42.​8201 CrossRef
  8.Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F, Investigators RS (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508. doi:10.​1016/​S1470-2045(15)70127-0 PubMed CrossRef
  9.Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963–969PubMed
  10.Ellis LM, Hicklin DJ (2008) Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clinical Cancer research : An Official Journal of the American Association for Cancer Research 14(20):6371–6375CrossRef
  11.Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299–309PubMed CrossRef
  12.Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol Off J Am Soc Clin Oncol 28 (3):453–459
  13.Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26(22):3709–3714PubMed CrossRef
  14.Grothey A, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Steen PD, Loui WS, Bot BM, Alberts SR, Reynolds JT (2010) Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C. ASCO Meeting Abstracts 28 (15_suppl):3549
  15.Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757–1765PubMed CrossRef
  16.Haaz MC, Rivory L, Riche C, Vernillet L, Robert J (1998) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 58(3):468–472PubMed
  17.Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P (2006) Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 57(5):685–692PubMed CrossRef
  18.Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92(10):1855–1861. doi:10.​1038/​sj.​bjc.​6602584 PubMed PubMedCentral CrossRef
  19.Duran I, Hotte SJ, Hirte H, Chen EX, MacLean M, Turner S, Duan L, Pond GR, Lathia C, Walsh S, Wright JJ, Dancey J, Siu LL (2007) Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 13(16):4849–4857. doi:10.​1158/​1078-0432.​CCR-07-0382 CrossRef
  20.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247PubMed CrossRef
  21.Loupakis F, Cremolini C, Antoniotti C, Lonardi S, Ronzoni M, Zaniboni A, Tonini G, Salvatore L, Chiara S, Carlomagno C, Banzi C, Negri F, Marcucci L, Barone C, Fontanini G, Borrelli N, Giordano M, Macerola E, Boni L, Falcone A (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses. ASCO Meeting Abstracts 33 (15_suppl):3510
  22.Sosman JA, Flaherty KT, Atkins MB, McDermott DF, Rothenberg ML, Vermeulen WL, Harlacker K, Hsu A, Wright JJ, Puzanov I (2008) Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). ASCO Meeting Abstracts 26 (15_suppl):5011
  23.Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, Garcia-Carbonero R, Manzano Mozo JL, Sevilla I, Duran I, Salazar R (2013) Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of spanish neuroendocrine tumour group (GETNE0801). Eur J Cancer 49(18):3780–3787. doi:10.​1016/​j.​ejca.​2013.​06.​042 PubMed CrossRef
  24.Hubbard JM, Alberts SR, Loui WS, Mahoney MR, Roberts LR, Smyrk TC, Gatalica Z, Kumar S, Dakhil SR, Flynn PJ, Lafky JM, Bury MJ, NCCTG (2011) Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745. ASCO Meeting Abstracts 29 (15_suppl):4116
  25.Mina LA, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R (2013) A phase II study of combined VEGF inhibitor (bevacizumab + sorafenib) in patients with metastatic breast cancer: hoosier oncology group study BRE06-109. Investig New Drugs 31(5):1307–1310. doi:10.​1007/​s10637-013-9976-1 CrossRef
  
• 作者单位：Joleen M. Hubbard (1)
  George Kim (2)
  Mitesh J. Borad (3)
  Elizabeth Johnson (4)
  Rui Qin (5)
  Janet Lensing (1)
  Suneetha Puttabasavaiah (1)
  John Wright (6)
  Charles Erlichman (1)
  Axel Grothey (1)
  
  1. Mayo Clinic Rochester, 200 First Street, SW, Rochester, MN, 55905, USA
  2. University of Florida Health Oncology, Jacksonville, FL, USA
  3. Mayo Clinic Scottsdale, Scottsdale, AZ, USA
  4. Mayo Clinic Jacksonville, Jacksonville, FL, USA
  5. Regeneron Pharmaceuticals, Basking Ridge, NJ, USA
  6. Investigational Drug Branch of the Cancer Therapy Evaluation Program, Bethesda, MD, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Pharmacology and Toxicology
  
• 出版者：Springer Netherlands
• ISSN：1573-0646

文摘